Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
RP 6306 is an inhibitor of membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (Myt1 kinase), also known as PKMYT1 (IC50 = 0.002 nM in a bioluminescence resonance energy transfer (BRET) assay).1 It is greater than 29-fold selective for Myt1 kinase over eight other kinases in BRET assays at 1.2 µM. RP 6306 (500 nM) increases the levels of DNA-associated γ histone H2AX (γH2AX), a marker of DNA damage, in hTERT FT 282 fallopian tube cells.2 It induces cell cycle arrest at the S phase in hTERT FT 282 cells. Dietary administration of RP 6306 (15, 50, or 300 ppm) reduces tumor volume in an OVCAR-3 ovarian cancer mouse xenograft model.1
WARNING This product is not for human or veterinary use.
1. Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-
2. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 604(7907), 749-756 (2022).